NextFin News - Jingfeng Medical (02675.HK) has reported a significant narrowing of its annual losses for the 2025 fiscal year, a period marked by the rapid commercialization of its flagship surgical robotic systems. The Shenzhen-based medtech firm saw its net loss shrink to RMB 88.61 million, a substantial improvement from the RMB 214 million deficit recorded in the previous year. This bottom-line recovery was fueled by a 184.8% surge in revenue, which reached RMB 456 million, as the company transitioned from a research-heavy biotech to a commercial-stage medical device powerhouse.
The revenue explosion is primarily attributed to the increased market penetration of the Edge Multi-Port Endoscopic Surgical Robot. Since receiving regulatory approvals, Jingfeng has aggressively expanded its footprint in China’s Tier-1 and Tier-2 hospitals, challenging the long-standing dominance of international incumbents like Intuitive Surgical’s Da Vinci system. The company’s ability to scale production while maintaining a leaner cost structure has allowed it to capture a growing share of the domestic minimally invasive surgery (MIS) market, which is currently undergoing a structural shift toward localized high-end manufacturing.
Despite the triple-digit revenue growth, the path to absolute profitability remains steep. Research and development expenses, though optimized, continue to represent a significant portion of the company’s cash outlay as it iterates on its single-port and natural orifice transluminal endoscopic surgery (NOTES) platforms. The 2025 results reflect a delicate balancing act: the company has managed to reduce its administrative and marketing overhead as a percentage of sales, yet it must continue to spend heavily to defend its technological moat against a wave of domestic competitors entering the robotic surgery space.
Market analysts tracking the sector note that Jingfeng’s performance is a bellwether for the broader "B-category" (pre-profit biotech) stocks on the Hong Kong Exchange. While the narrowing loss is a positive signal, some institutional investors remain cautious about the long-term pricing pressure from China’s centralized volume-based procurement (VBP) programs. Although surgical robots have largely remained outside the harshest VBP mandates thus far, the increasing adoption of these systems makes them a likely target for future cost-containment measures by provincial health authorities.
The company’s liquidity position appears stable following its 2025 capital raising activities, including the exercise of over-allotment options. However, the sustainability of its current growth trajectory depends on the successful rollout of its next-generation bronchoscope and orthopedic robots. As the domestic market becomes more crowded, Jingfeng’s ability to maintain its premium pricing while scaling volume will be the primary determinant of whether it can reach a break-even point by the end of the 2026 fiscal year.
Explore more exclusive insights at nextfin.ai.
